Ólöf Vigdís Ragnarsdóttir

Actavis Group hf develops, manufactures and sells generic pharmaceuticals. The company was founded in 1957 and is headquartered in Hafnarfjörður, Iceland.

ALMC hf provides investment banking services. Its activities include proprietary trading, corporate finance, debt finance, treasury, capital markets, and asset management. The company is headquartered in Reykjavik, Iceland.

Nýsköpunarsjóður atvinnulífsins (Nýsköpunarsjóður atvinnulífsins) is a venture capital subsidiary of government of Iceland founded in 1998. The firm is headquartered in Reykjavík.

Novator AB provides drilling solutions for the aerospace industry. The firm’s technology Orbital Drilling, is created by combining three motions-feed, spindle rotation and orbital rotation - resulting in a helical movement of the tool through the material; and SmartTemplates, which is a bushing identifications system utilizing radio-frequency identification technology to provide fail safe drilling. The company was founded by Ingvar Eriksson in 1992 and is headquartered in Spanga, Sweden.

H.F. Securities hf provides capital market and corporate finance services. It offers government bonds, equity and claims and other distresses Icelandic assets; direct market access and issues and listing services. The company also provides mergers and acquisitions, financial restructuring, IPOS, issues and listing, and funding and debt advisory services. H.F. Securities was founded by Halldor Fridrik Thorsteinsson on December 16, 2003 and is headquartered in Reykjavík, Iceland.

Zymetech ehf specializes in research, development and manufacturing of marine-derived enzymes and innovative formulations for the health and beauty industries. The firm’s products include Dermacosmetics - Marine Marvels line, DermiZyme, and PreCold. Its product Penzim, which is used for relief from skin conditions, rheumatic or arthritic diseases, swelling, and muscle pains. The company was founded by Jón Bragi Bjarnason in 1999 and is headquartered in Reykjavik, Iceland.

Baliopharm GmbH operates as biotechnology company. It develops a novel therapeutics for the treatment of autoimmune diseases like rheumatoid arthritis, Crohn`s disease, psoriasis and multiple sclerosis, and for cancer. The company was founded in 2011 and is headquartered in Juelich, Germany.

Baliopharm AG operates as a biotechnology company. It develops a novel therapeutics for the treatment of autoimmune diseases like rheumatoid arthritis, psoriasis and multiple sclerosis and for cancer. The company was founded in 2011 and is headquartered in Basel, Switzerland.

Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland.

Straumur Investment Bank hf provides financial advisory and securities brokerage services. The private company is based in Reykjavík, Iceland.

Risk ehf. provide healthcare services. The firm offer services to optometrists, ophthalmologists, primary care physicians, diabetes services. The company was founded by Enar Stefánsson and Arna Guomundsdóttir in 2009 and is headquartered in Reykjavík, Iceland.

Part of VERAXA Biotech GmbH, SYNIMMUNE GmbH is a biotechnology company based in Tuebingen, Germany. The German company is dedicated to developing innovative and effective mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with a focus on orphan hematopoietic malignancies. SYNIMMUNE's lead product candidate is the flt3 specific antibody flysyn, which was recently tested in a first-in-human phase i/ii clinical study in aml patients. The CEOs are Ludger Große-Hovest, Martin Steiner. SYNIMMUNE GmbH was founded in 2010 by Gundram Jung, Hans-Georg Rammensee, Ludger Große-Hovest, Steffen Aulwurm, Andreas Herrmann. SYNIMMUNE was acquired by VERAXA Biotech GmbH on December 29, 2023 for $35.54 million.